Welcome to the Institute of Clinical Research

Welcome to the Institute of Clinical Research

About Us

The Institute of Clinical Research (ICR) is the probably the oldest independent membership-led professional body for global clinical researchers.  

For over 40 years, The Institute of Clinical Research (ICR) has provided high quality training, networking and support to the clinical research community.  For many Members the Institute has been part of their life throughout their working careers, many have been with the Institute since its first incarnation as the ACRPI.

It is the membership that makes the Institute.

How does it all work ?

The Institute of Clinical Research is you, the Membership governed by the Articles of Memorandum drawn up by the founding members.

The Board is made up of members who give their time freely to guide the future direction of the ICR.

The ICR Secretariat is the administrative arm of the Institute, its primary focus is to ensure that the wishes of the Board and Membership are carried out and to see to the day to day tasks that any membership organisation generates.

  

Our Mission

The ICR exists to support our members through all stages of their careers. We do this, in part, by:

  • Defining and refining standards for our profession
  • Providing a forum for discussion of key issues impacting clinical research
  • Promoting good relations with other healthcare related groups 
  • Providing opportunities for learning and development to enhance professional competence 
  • Enhancing public confidence and understanding of clinical research

 

Current News

NICE recommendation expands patient eligibility for AbbVie’s Ozurdex

By ICR Secretariat / 18/08/2022 03:38 PM

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending the dexameth…

Amgen’s low tax rates draw attention of top Democratic senator

By ICR Secretariat / 18/08/2022 03:23 PM

Last year, Amgen paid taxes equivalent to just over 12% of its nearly $7 billion in pre-tax profits, well below the U.S. corporate rate of 21%. The ye…

2 deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again

By ICR Secretariat / 18/08/2022 03:16 PM

Novartis has recorded two deaths after treatment with its spinal muscular atrophy gene therapy Zolgensma, once again bringing gene therapy’s safety in…


FDA approves AstraZeneca, Daiichi drug in breast cancer first

By ICR Secretariat / 11/08/2022 03:28 PM

A new targeted treatment for breast cancer could reshape how doctors classify and treat the disease, offering another option for people whose tumors h…

The most significant FDA citations of 2021-2022

By ICR Secretariat / 11/08/2022 02:31 PM

While the FDA's inspection activities suffered amid the COVID-19 pandemic, several notable citations surfaced over the past year and a half. Those reb…

How a small UK biotech ended up in Gilead’s hands

By ICR Secretariat / 11/08/2022 02:21 PM

Gilead Sciences will acquire U.K.-based startup MiroBio, which is developing antibody drugs for autoimmune disorders, in a $405 million deal announced…


Aiming to avoid Pfizer's Eucrisa failure, Arcutis wins FDA nod for Zoryve cream in psoriasis

By ICR Secretariat / 04/08/2022 01:38 PM

Pfizer once harbored blockbuster hopes for Eucrisa to be the next big topical treatment for inflammatory skin diseases. But the ointment never gained …

Tallac announces first patient treated with TAC-001

By ICR Secretariat / 04/08/2022 01:29 PM

Tallac Therapeutics has announced that the first patient has been treated with TAC-001 in a phase 1/2 clinical trial for patients with advanced or met…

US secures updated COVID boosters in $1.7B deal with Moderna

By ICR Secretariat / 04/08/2022 01:15 PM

The U.S. government has reached a deal with Moderna to buy 66 million doses of the biotechnology company’s updated COVID-19 booster shot this year, pr…


ICR Autumn ONLINE Ethics & GCP Forum

By ICR Secretariat / 01/08/2022 03:53 PM

We are delighted to announce that we will be running our Autumn Ethics & GCP Forum online via Zoom on the 11th October 2022. If you are unavailabl…

FDA puts the microscope on 2 more cancer approvals without voluntary withdrawals

By ICR Secretariat / 01/08/2022 03:50 PM

The FDA’s oncology department has lately been tightening its act around accelerated approvals and stressing the importance of patient survival data. S…

NHS app reaches new milestone

By ICR Secretariat / 01/08/2022 03:48 PM

The NHS App enabled 1.8 million repeat prescriptions to be ordered in June 2022 alone


After failed Alzheimer's launch, Biogen writes off the remaining value of its Aduhelm inventory

By ICR Secretariat / 01/08/2022 03:37 PM

Biogen is trying to escape the dark Aduhelm cloud hanging over its Alzheimer's disease drug launch. So far, the launch has triggered layoffs, a CEO sw…

Royalty Pharma buys rights to top-selling GSK drug in pair of deals

By ICR Secretariat / 21/07/2022 02:56 PM

  • Royalty Pharma, which calls itself the largest buyer of biopharmaceutical royalties, said Wednesday it’s undertaking a two-pronged transaction to ac…

Roche’s combination breast cancer treatment delivers positive results

By ICR Secretariat / 21/07/2022 02:51 PM

Roche, the Breast International Group, Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation have announced updated data …


AstraZeneca continues Farxiga push, enlists Health2Sync for a digital approach to diagnosing kidney disease

By ICR Secretariat / 21/07/2022 02:47 PM

AstraZeneca is going all out for its new Farxiga kidney disease label: This year, it’s already started a new DTC campaign for the drug, and it more re…

Diabetes patients to benefit from £10m heart disease data investment

By ICR Secretariat / 14/07/2022 03:27 PM

People living with diabetes could be set to benefit from a major research initiative aimed at establishing a link between diabetes and heart disease –…

10 clinical trials to watch in the second half of 2022

By ICR Secretariat / 14/07/2022 03:26 PM

Highly anticipated study readouts in cancer, Alzheimer’s disease and schizophrenia could determine whether the biotech industry’s slump continues.


NICE recommends Opdivo as post-surgery treatment

By ICR Secretariat / 14/07/2022 03:25 PM

Bristol Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recomm…

Novartis, staring down tough market for M&A, leans toward $25B Sandoz spinoff: Bloomberg

By ICR Secretariat / 08/07/2022 02:33 PM

For months, the industry has waited patiently as Novartis mulls the fate of its $25 billion generics arm. Now, it appears a spinoff could be in the ca…

First treatment for ‘broken heart syndrome’ trialled

By ICR Secretariat / 08/07/2022 02:30 PM

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Ab…


5 FDA decisions to watch in the third quarter

By ICR Secretariat / 08/07/2022 02:25 PM

So far in 2022, the Food and Drug Administration’s main review office has approved 16 new medicines. The agency has recently cleared between 45 to 50 …

Novartis lung cancer drug Tabrecta gets approval

By ICR Secretariat / 30/06/2022 01:30 PM

Novartis has announced that the European Commission (EC) has approved Tabrecta – also known as capmatinib – as a monotherapy for the treatment of adul…

UCB lowers 2022 profit expectations amid Ukraine war, rising costs

By ICR Secretariat / 30/06/2022 01:29 PM

Generic competition, a complete response letter, a new acquisition and external pressures have created a perfect storm for UCB, leading the company to…


Sanofi and GSK report successful efficacy results against Omicron

By ICR Secretariat / 30/06/2022 01:28 PM

Sanofi and GSK have announced positive data from their vaccine trial which evaluated an adjuvanted Beta vaccine candidate. This included 75.1% efficac…

NICE recommends Eli Lilly’s breast cancer therapy

By ICR Secretariat / 27/06/2022 10:49 AM

Verzenios in combination with endocrine treats people with early breast cancer who are at high-risk of recurrence

Roche Alzheimer's study fails in another setback to a long-tested hypothesis

By ICR Secretariat / 27/06/2022 10:48 AM

An experimental and closely followed drug for Alzheimer’s disease has failed a key clinical study, dealing yet another blow to the prevailing theory o…


Amid death risk fears, Clovis pulls Rubraca in 3rd-line ovarian cancer as PARP player plugs away at earlier setting

By ICR Secretariat / 27/06/2022 10:36 AM

A death risk signal has taken a toll on Clovis Oncology’s already lagging ovarian cancer drug, Rubraca. The company has taken FDA's hint, withdrawing …

FDA advisers offer unanimous support to second Bluebird gene therapy

By ICR Secretariat / 21/06/2022 03:27 PM

For the second time in two days, advisers to the Food and Drug Administration gave their unanimous support to an experimental gene therapy for a rare …

Fierce Pharma Asia—Enhertu's standing ovation; Tessa's $126M CAR-T financing; Samsung's manufacturing deal

By ICR Secretariat / 21/06/2022 03:26 PM

AstraZeneca and Daiichi Sankyo's Enhertu looked on track to open a new breast cancer category: HER2-low. Singapore's Tessa Therapeutics grabbed $126 m…


GSK claims first positive Phase 3 result for an RSV vaccine

By ICR Secretariat / 21/06/2022 03:25 PM

  • GSK’s experimental vaccine for respiratory syncytial virus prevented disease in adults 60 and older, the company said Friday, clearing the way for t…

Regeneron's cholesterol drug war heats up with lawsuit over Amgen's 'illegal' bundling scheme

By ICR Secretariat / 15/06/2022 11:01 AM

Since their PCSK9 drugs to lower bad cholesterol won FDA approvals a month apart in the summer of 2015, Amgen and Regeneron have waged a war for supre…

Bristol Myers’ autoimmune drug shows potential in lupus

By ICR Secretariat / 15/06/2022 10:59 AM

  • Bristol Myers Squibb’s experimental autoimmune disease drug deucravacitinib helped treat moderate-to-severe lupus in a Phase 2 trial, the company re…


Pfizer topples oncology giant Roche in cancer patient groups' reputation list

By ICR Secretariat / 15/06/2022 10:32 AM

Pfizer has become the most reputable pharma company for cancer patient groups, knocking Roche out of the top spot.

Thousands to potentially benefit from Roche treatment for sight loss

By ICR Secretariat / 06/06/2022 11:30 AM

The National Institute for Health and Care Excellence (NICE) has recommended Roche’s faricimab (Vabysmo) as a treatment option for two leading forms o…

Idorsia taps more star power, enlisting actor Taye Diggs to pitch newly launched insomnia drug Quviviq

By ICR Secretariat / 06/06/2022 11:29 AM

Count Broadway star Taye Diggs as the latest addition to sleep drug maker Idorsia’s celebrity arsenal. Just a few weeks after its insomnia drug Quvivi…


Merck study results signal blood cancer potential for new type of immunotherapy

By ICR Secretariat / 06/06/2022 11:27 AM

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Mer…

ICR Project Management Forum - Friday 30th September at IQVIA - Reading

By ICR Secretariat / 30/05/2022 02:56 PM

We are pleased to announce our annual Project Management Forum will be held on

Friday 30th September at IQVIA - Reading

Understanding Project Manage…

GlaxoSmithKline is no more: Meet the scaled down 'GSK'

By ICR Secretariat / 25/05/2022 11:48 AM

More than two decades ago, Glaxo Wellcome and SmithKline Beecham combined to become GlaxoSmithKline. But as the British Big Pharma looks to slim down …


NHS patients missing out on new medicines that could extend lives

By ICR Secretariat / 25/05/2022 11:43 AM

Data shows that 1.2 million additional NHS patients are currently eligible for vital medicines but are missing out

Most influential people in biopharma—the entrepreneurs

By ICR Secretariat / 25/05/2022 11:20 AM

This is the third week in our Most Influential People in Biopharma series, following features on CEOs and scientists earlier this month. The last sect…

FDA rejects two China-developed cancer drugs

By ICR Secretariat / 19/05/2022 03:45 PM

The Food and Drug Administration has refused to approve two cancer treatments developed by Chinese drugmakers, citing trial design in one rejection an…


University launches hub for pregnant women with pre-existing medical conditions

By ICR Secretariat / 19/05/2022 03:44 PM

Norfolk and Norwich University Hospitals Foundation Trust opens centre to increase survival rate among pregnant women managing other conditions

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

By ICR Secretariat / 19/05/2022 03:42 PM

  • A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form of lung…

With 200M unused doses, AstraZeneca's COVID vaccine partner Serum Institute halts production

By ICR Secretariat / 28/04/2022 02:51 PM

About 200 million doses of COVID-19 vaccine are gathering dust in warehouses of the world’s largest vaccine manufacturer as global demand ebbs.


How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials

By ICR Secretariat / 28/04/2022 02:48 PM

The outcome, no longer seen as a sure bet, could influence how future drugs for a deadly heart disease are developed.

DNA analysis uncovers new cancer treatment clues

By ICR Secretariat / 28/04/2022 02:45 PM

Researchers were able to detect specific combinations of genetic alterations which may hold key to the growth of cancers

Troubling data leads a biotech to pull its prized drug from market and FDA review

By ICR Secretariat / 21/04/2022 02:59 PM

  • The New York-based biotechnology company TG Therapeutics has decided to pull its only approved medicine from the market, after recent clinical trial…


Course Postponements Due to Covid

By ICR Secretariat / 10/02/2022 03:38 PM

All of our delegates and members who had course places postponed over the last two years due to covid restrictions/illness have now been contacted dir…



Events and Courses

Introduction To Clinical Trials & Clinical Trials Practice L20

An Introduction to Clinical Trials and Clinical Trial Practice, the ICR’s flagship training course, is accredited by Cranfield University. This h...


Clinical Investigations for Medical Devices - Foundation L21

In this one day course we explore clinical investigations for medical devices.  We will review the latest legislation and its impact on determini...


Process Thinking in Clinical Trials L22

ICH E6 (R2) has emphasized the importance of risk management in relation to ensuring subject safety and rights as well as data integrity in clinica...


Advanced Monitoring L29

In this highly practical course we look at the root cause of typical inspection findings and work with delegates to develop personal corrective a...


Project Management Forum CT

Understanding Project Management can be a ni...


The ICR Ethics & GCP Forum EGCP

The ICR Ethics and GCP Forum provides an excellent opportunity to:  Keep up to date with current ethical and clinical r...


Current Jobs